You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Epirubicin-cyclophosphamide dose-dense

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Localized Breast Cancer Trial in Dijon (Dense dose epirubicin-cyclophosphamide chemo and G-CSF (filgrastim, lenograstim), Dense

Not yet recruiting
  • Localized Breast Cancer
  • Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)
  • Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)
  • Dijon, Bourgogne, France
    Centre Georges François Leclerc (CGFL)
Mar 24, 2022

HER2-negative Breast Cancer, Neoadjuvant Chemo Trial in Hangzhou (Epirubicin, Cyclophosphamid, Docetaxel)

Recruiting
  • HER2-negative Breast Cancer
  • Neoadjuvant Chemotherapy
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Aug 9, 2021

Breast Cancer, Triple Negative Breast Cancer, Luminal B Trial in Belgium (Paclitaxel, Epirubicin, Cyclophosphamide)

Active, not recruiting
  • Breast Cancer
  • +2 more
  • Charleroi, Hainaut, Belgium
  • +3 more
Aug 2, 2022

Stage III Breast Cancer AJCC V7 Trial in Bergen (epirubicin/docetaxel sequential)

Active, not recruiting
  • Stage III Breast Cancer AJCC V7
  • epirubicin/docetaxel sequential
  • Bergen, Norway
    Dept of Oncology
Jun 24, 2022

Breast Cancer Trial in Frankfurt (Epirubicin, nab-Paclitaxel, Cyclophosphamide)

Completed
  • Breast Cancer
  • Frankfurt, Hessen, Germany
    Klinikum Frankfurt Höchst
Feb 1, 2021

Early-stage Breast Cancer Trial in Ottawa (Granulocyte Colony-Stimulating Factor (G-CSF), Omission of Granulocyte

Not yet recruiting
  • Early-stage Breast Cancer
  • Granulocyte Colony-Stimulating Factor (G-CSF)
  • Omission of Granulocyte Colony-Stimulating Factor (G-CSF)
  • Ottawa, Ontario, Canada
    The Ottawa Hospital Cancer Centre
Feb 22, 2023

Triple Negative Breast Cancer Trial in Worldwide (Atezolizumab, Paclitaxel, Dose-dense Doxorubicin or dose-dense Epirubicin)

Active, not recruiting
  • Triple Negative Breast Cancer
  • Concord, California
  • +429 more
Dec 12, 2022

Early Stage Breast Cancer Trial in United States (Paclitaxel, Neulasta)

Completed
Has Results
  • Early Stage Breast Cancer
  • Boston, Massachusetts
  • +3 more
Apr 11, 2022

Adjuvant Chemotherapy With Epirubicin, CMF, and Weekly Docetaxel

Completed
  • Breast Cancer
  • Adenocarcinoma of Breast
    • (no location specified)
    Apr 2, 2021

    Breast Cancer Trial in Belgium (Paclitaxel, Carboplatinum, Epirubicin)

    Completed
    • Breast Cancer
    • Aalst, Belgium
    • +17 more
    Jan 13, 2020

    Locally Advanced Breast Cancer Trial in New York (Docetaxel, Carboplatin, Trastuzumab)

    Terminated
    • Locally Advanced Breast Cancer
    • New York, New York
    • +2 more
    Oct 18, 2021

    Breast Cancer Trial in Boston, Hooksett (Doxorubicin, Cyclophosphamide, Paclitaxel)

    Completed
    Has Results
    • Breast Cancer
    • Boston, Massachusetts
    • +3 more
    Apr 26, 2021

    Breast Cancer Trial in United States (Gemcitabine, Epirubicin, Albumin-bound Paclitaxel)

    Completed
    Has Results
    • Breast Cancer
    • Fort Myers, Florida
    • +12 more
    Nov 22, 2021

    Breast Tumor Trial in China (Epirubicin plus Cyclophosphamide, Taxanes, Taxanes plus Carboplatin)

    Recruiting
    • Breast Neoplasm
    • Epirubicin plus Cyclophosphamide
    • +2 more
    • Fuding, Fujian, China
    • +26 more
    Mar 28, 2022

    Colorectal Cancer Metastatic, Colorectal Cancer Stage IV, TP53 Gene Mutation Trial in Bergen (Cyclophosphamide)

    Terminated
    • Colorectal Cancer Metastatic
    • +2 more
    • Bergen, Norway
      Haukeland University Hospital
    Jan 20, 2021

    Breast Cancer, Triple Negative Breast Cancer Trial (Antivascular therapy, Chemotherapy)

    Not yet recruiting
    • Breast Cancer
    • Triple Negative Breast Cancer
    • (no location specified)
    Jun 11, 2023

    Breast Cancer, Triple Negative Breast Cancer Trial in United States (Carboplatin, Paclitaxel, Doxorubicin)

    Active, not recruiting
    • Breast Cancer
    • Triple Negative Breast Cancer
    • Rockford, Illinois
    • +5 more
    Mar 29, 2021

    TNBC - Triple-Negative Breast Cancer Trial (epirubicin,cyclophosphamide,paclitaxel,Carrelizumab,

    Not yet recruiting
    • TNBC - Triple-Negative Breast Cancer
    • (no location specified)
    May 8, 2023

    Breast Cancer Trial in Shanghai (Pegylated liposomal doxorubicin, Epirubicin, Cyclophosphamid)

    Recruiting
    • Breast Cancer
    • Pegylated liposomal doxorubicin
    • +5 more
    • Shanghai, China
      Shanghai Pudong Hospital
    Dec 11, 2022

    Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

    Recruiting
    • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jun 12, 2023

    Breast Cancer Trial in Hangzhou (Docetaxel, Carboplatin, Trastuzumab)

    Recruiting
    • Breast Cancer
    • Hangzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Jun 28, 2022

    Triple Negative Breast Cancer Trial in Beijing (Epirubicin, Cyclophosphamide, Paclitaxel)

    Recruiting
    • Triple Negative Breast Cancer
    • Beijing, Beijing, China
      National Cancer Center, Cancer Hospital/Chinese Academy of Medic
    Mar 20, 2019

    HER2-negative Breast Cancer, Advanced Solid Tumor Trial in Singapore (ADG106, Doxorubicin, Cyclophosphamide)

    Recruiting
    • HER2-negative Breast Cancer
    • Advanced Solid Tumor
    • Singapore, Singapore
      National University Hospital
    Jun 9, 2022

    Tissue Samples From Women Who Underwent Chemotherapy for Lymph

    Completed
    • Breast Cancer
    • Saint Louis, Missouri
      Washington University
    Aug 16, 2021

    Breast Cancer Trial in Houston (Panitumumab, Nab-paclitaxel, Carboplatin)

    Completed
    Has Results
    • Breast Cancer
    • Houston, Texas
      University of Texas MD Anderson Cancer Center
    Sep 20, 2022